Study of prognostic biomarkers in infective endocarditis

• Grant number: 15/05165-3
• Support Opportunities: Regular Research Grants
• Start date: July 01, 2015
• End date: June 30, 2017
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Rinaldo Focaccia Siciliano
• Grantee: Rinaldo Focaccia Siciliano
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Alexandre de Matos Soeiro ; Alfredo José Mansur ; Bruno Caramelli ; Celia Maria Cassaro Strunz ; Danielle Menosi Gualandro ; Fabiana Goulart Marcondes Braga ; Fernando Bacal ; Flávio Tarasoutchi ; Mucio Tavares de Oliveira Junior ; Tânia Mara Varejão Strabelli

Abstract

Aims:Evaluate the use of biomarkers as predictors of in-hospital death and a combined endpoint (in-hospital death or cardiac surgery) Methods Type of Study Prospective observational cohort studyInstitutionHeart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, BrazilCasuistic70 patientsInclusion Criteria: Age greater than 18 years *Suspected endocarditis at discretion of the attending physician, Patients who sign the Informed Consent FormExclusion Criteria: Patients who do not fulfill Duke´s criteria for possible or definite endocarditis after performing diagnostic tests, Use of intravenous antibiotic therapy for more than 72h before enrollment Procedures We will include consecutive patients admitted to the Emergency Department with suspected endocarditis. Enrollment will be done through daily active search by the study investigators. Sample for biomarkers will be obtained at study inclusion and on day 8 after antibiotic initiation.*All samples will be stored at -80oC and results will be available only after the end of follow-up.The follow biomarkers will be studied: C-reactive protein, procalcitonin, BNP, high-sensitivity cardiac troponin, ST2, exhaled acetone, copeptin, soluble urokinase-type plasminogen activator receptor (suPAR), adrenomodullin and Cystatin C. (AU)